More mol­e­c­u­lar glue: Plex­i­um pens Ab­b­Vie pact months af­ter Am­gen deal

A few months af­ter its deal with Am­gen, San Diego-based biotech Plex­i­um has inked a deal with an­oth­er Big Phar­ma – this time, it’s Ab­b­Vie.

While Am­gen’s deal fo­cused on the can­cer space, Ab­b­Vie hopes to use Plex­i­um’s “ag­nos­tic” tar­get­ed pro­tein degra­da­tion (TPD) plat­form to screen for new ther­a­pies for neu­ro­log­i­cal dis­eases, Plex­i­um an­nounced to­day.

The deal in­cludes $35 mil­lion up­front and $530 mil­lion in down­stream mile­stones, along with fu­ture roy­al­ties for each of the five un­spec­i­fied tar­gets that Plex­i­um will be screen­ing for new ther­a­pies, Plex­i­um CEO Per­ci­val Bar­ret­to-Ko told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER